Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash & Equivalents (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Cash & Equivalents for 9 consecutive years, with $91.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents changed N/A to $91.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $91.0 million, a N/A change, with the full-year FY2024 number at $175.0 million, up 37.65% from a year prior.
  • Cash & Equivalents was $91.0 million for Q3 2025 at Denali Therapeutics, down from $175.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $485.7 million in Q2 2021 to a low of $68.1 million in Q1 2023.
  • A 5-year average of $201.7 million and a median of $132.0 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 254.04% in 2021, then plummeted 43.41% in 2024.
  • Denali Therapeutics' Cash & Equivalents stood at $293.5 million in 2021, then fell by 25.7% to $218.0 million in 2022, then plummeted by 41.71% to $127.1 million in 2023, then surged by 37.65% to $175.0 million in 2024, then crashed by 48.01% to $91.0 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Cash & Equivalents are $91.0 million (Q3 2025), $175.0 million (Q4 2024), and $74.7 million (Q2 2024).